Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of 90Y-hLL2 in Non-Hodgkin's Lymphoma
NCT00061425Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- Aug 2000
- Primary completion
- Nov 2007
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
01
Overview
Phase 2, open-label, single-arm trial of 90Y-epratuzumab tetraxetan in Non-Hodgkin lymphoma (NHL), sponsored by Gilead Sciences. Primary endpoint: Safety and Adverse Events. Started Aug 2000; status: completed.
02
Drugs
90Y-epratuzumab tetraxetan
03
Conditions
Non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT00061425.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00061425.